CA2759180A1 - Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof - Google Patents

Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof Download PDF

Info

Publication number
CA2759180A1
CA2759180A1 CA2759180A CA2759180A CA2759180A1 CA 2759180 A1 CA2759180 A1 CA 2759180A1 CA 2759180 A CA2759180 A CA 2759180A CA 2759180 A CA2759180 A CA 2759180A CA 2759180 A1 CA2759180 A1 CA 2759180A1
Authority
CA
Canada
Prior art keywords
transnorsertraline
disorder
pain
pharmaceutically acceptable
serotonin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2759180A
Other languages
English (en)
French (fr)
Inventor
Una Campbell
Judith Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CA2759180A1 publication Critical patent/CA2759180A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2759180A 2009-05-13 2010-05-12 Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof Abandoned CA2759180A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17799709P 2009-05-13 2009-05-13
US61/177,997 2009-05-13
PCT/US2010/034473 WO2010132521A1 (en) 2009-05-13 2010-05-12 Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof

Publications (1)

Publication Number Publication Date
CA2759180A1 true CA2759180A1 (en) 2010-11-18

Family

ID=42306730

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759180A Abandoned CA2759180A1 (en) 2009-05-13 2010-05-12 Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Country Status (6)

Country Link
US (1) US20120077818A1 (https=)
EP (1) EP2429514A1 (https=)
JP (2) JP2012526832A (https=)
CN (1) CN102573823B (https=)
CA (1) CA2759180A1 (https=)
WO (1) WO2010132521A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
WO2011064769A1 (en) * 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
NZ600107A (en) * 2009-12-04 2014-10-31 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and uses thereof
JP6436024B2 (ja) 2015-09-14 2018-12-12 住友電気工業株式会社 炭化珪素エピタキシャル基板の製造方法
JP2021512057A (ja) * 2018-01-19 2021-05-13 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 経口製剤
WO2019182915A1 (en) * 2018-03-19 2019-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
WO2025049588A1 (en) * 2023-08-29 2025-03-06 The Trustees Of Indiana University Novel treatments for optic neuropathies and glaucoma
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810518A (ja) * 1981-07-14 1983-01-21 Kowa Yakuhin Kogyo Kk アルコ−ル中毒または鎮静催眠薬中毒治療剤
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
IL91451A0 (en) * 1988-08-30 1990-04-29 Bristol Myers Co Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
US5468749A (en) * 1988-08-30 1995-11-21 Gawin; Frank H. Method for treatment of substance addiction
IL97054A (en) * 1990-02-12 1995-10-31 Bristol Meyers Squibb Co Pharmaceutical preparations containing bospirone for the treatment of coma
JPH03246225A (ja) * 1990-02-20 1991-11-01 Bristol Myers Squibb Co メランコリーうつ病の治療法
JPH04327532A (ja) * 1991-01-31 1992-11-17 Bristol Myers Squibb Co 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
EP0818198A1 (en) * 1996-07-09 1998-01-14 Lilly S.A. Potentiation of drug response by increasing serotonin availability
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
SK14502000A3 (sk) * 1998-05-08 2001-05-10 Pharmacia And Upjohn Company Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
JP2002020291A (ja) * 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
ATE409475T1 (de) * 2001-02-20 2008-10-15 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
US20020183306A1 (en) * 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
JP2003335678A (ja) * 2002-05-17 2003-11-25 Sumitomo Pharmaceut Co Ltd 神経因性疼痛治療薬
JP4610336B2 (ja) * 2002-09-16 2011-01-12 セプラコール インク． トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療
JP2008513430A (ja) * 2004-09-17 2008-05-01 ニューロキュア リミテッド 月経前症候群および月経前不快気分障害の処置のためのピンドロール
US20080262071A1 (en) * 2004-09-17 2008-10-23 Timothy Dinan Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
JP2009500425A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
AR058033A1 (es) * 2005-09-09 2008-01-23 Wyeth Corp Composiciones y formas de dosificacion farmaceuticas
AU2007254751A1 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide

Also Published As

Publication number Publication date
EP2429514A1 (en) 2012-03-21
CN102573823B (zh) 2015-01-07
WO2010132521A1 (en) 2010-11-18
CN102573823A (zh) 2012-07-11
JP2012526832A (ja) 2012-11-01
JP2015180673A (ja) 2015-10-15
US20120077818A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
US20120077818A1 (en) Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
ES2261234T3 (es) Metabolitos de bupropion y metodos de sintesis y uso.
EP1759701B1 (en) Buproprion Metabolites for treating dementia and other cerebrovascular disorders
US20180071230A1 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
JP2014224143A (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
RU2446794C2 (ru) Терапия с интервалами для лечения тиннитуса
JP2002255820A (ja) モノアミン作動性神経の活性化剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150512

FZDE Discontinued

Effective date: 20171128